An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Trial Profile

An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2011

At a glance

  • Drugs Fostamatinib; Pioglitazone
  • Indications Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 06 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2011 Last checked against ClinicalTrials.gov record.
    • 29 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top